Gregory Ford

Title: Gregory Ford: Innovator in Anergy Associated Genes

Introduction

Gregory Ford is a notable inventor based in Sunnyvale, CA (US). He has made significant contributions to the field of immunology through his research and innovations. His work focuses on understanding the mechanisms of T cell anergy, which has implications for cancer treatment and autoimmune diseases.

Latest Patents

Ford holds a patent for "Anergy associated genes," which includes isolated nucleic acid compositions and sequences of anergy associated genes, notably the novel GRAIL gene. This patent highlights the upregulation of these genes during the early stages of anergy induction. The murine GRAIL sequence is shown to attenuate IL-2 transcription in T cells during their response to antigenic stimulation. The identification of these genes is crucial for evaluating the pathophysiology of cancer, autoimmune diseases, and transplant rejection. Furthermore, the genetic sequences involved in anergy induction serve as useful markers in assessing specific immunotherapies.

Career Highlights

Gregory Ford is affiliated with Leland Stanford Junior University, where he continues to advance his research in immunology. His work has garnered attention for its potential to manipulate T cell responses in human diseases. The functional characterization of genes involved in anergy induction allows for a deeper understanding of the mechanisms behind T cell anergy, including the transcriptional blockade of IL-2.

Collaborations

Ford has collaborated with notable colleagues such as Debra Bloom and C. Garrison Fathman. Their combined expertise contributes to the advancement of research in the field of immunology.

Conclusion

Gregory Ford's innovative work in the area of anergy associated genes has the potential to significantly impact the fields of cancer therapy and immunotherapy. His contributions continue to pave the way for new treatments and a better understanding of immune responses.